ArticleTheranostics2020

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

Theresa Osl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.